(NASDAQ: IGMS) Igm Biosciences's forecast annual revenue growth rate of 67.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Igm Biosciences's revenue in 2025 is $2,679,000.On average, 2 Wall Street analysts forecast IGMS's revenue for 2025 to be $770,206,055, with the lowest IGMS revenue forecast at $104,606,954, and the highest IGMS revenue forecast at $1,435,805,156. On average, 1 Wall Street analysts forecast IGMS's revenue for 2026 to be $256,436,475, with the lowest IGMS revenue forecast at $256,436,475, and the highest IGMS revenue forecast at $256,436,475.
In 2027, IGMS is forecast to generate $867,341,083 in revenue, with the lowest revenue forecast at $320,993,909 and the highest revenue forecast at $1,413,688,257.